Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
New York State Teachers Retirement System trimmed its position in The Carlyle Group Inc. (NASDAQ:CG – Free Report) by 0.7% during the 4th quarter, HoldingsChannel reports. The firm owned 44,246 shares ...
Q4 2024 Earnings Call Transcript February 11, 2025 The Carlyle Group Inc. misses on earnings expectations. Reported EPS is $0 ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
AlpInvest Secondaries Fund VIII has raised nearly $9.4 billion as of 31 December 2024, according to materials prepared for ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...
The Carlyle Group has announced the listing of its portfolio company Hexaware Technologies, a global IT services company, on the Bombay Stock Exchange and National Stock Exchange in India. The total ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback